Sir Mortimer B. Davis - Jewish General Hospital
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sir Mortimer B. Davis - Jewish General Hospital sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Sir Mortimer B. Davis - Jewish General Hospital: 4 sponsored US clinical trials, 2 recruiting.
Sir Mortimer B. Davis - Jewish General Hospital sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer Surgery, with 1 trials.
Upper-quartile sponsor footprint
Sir Mortimer B. Davis - Jewish General Hospital sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
NCT06888388
No Surgery Trial / Two Dose-escalation Strategies
NCT03051464
The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome
NCT00143598
Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial
NCT01615705
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Sir Mortimer B. Davis - Jewish General Hospital pipeline
2 recruiting of 4 indexed (50% open); 2 completed (50%).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Breast Cancer Surgery (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sir Mortimer B. Davis - Jewish General Hospital: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Sir Mortimer B. Davis - Jewish General Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Sir Mortimer B. Davis - Jewish General Hospital page
4 registered trials is a research-attention snapshot, not an endorsement of Sir Mortimer B. Davis - Jewish General Hospital or any single study.
- 2 of Sir Mortimer B. Davis - Jewish General Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer Surgery is the condition Sir Mortimer B. Davis - Jewish General Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer Surgery trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sir Mortimer B. Davis - Jewish General Hospital pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.